ADMA Biologics Inc (ADMA)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 138,983 | -3,212 | -46,625 | -58,591 | -63,763 |
| Long-term debt | US$ in thousands | 72,337 | 130,594 | 142,833 | 94,866 | 92,969 |
| Total stockholders’ equity | US$ in thousands | 349,018 | 135,206 | 151,974 | 141,173 | 88,249 |
| Return on total capital | 32.98% | -1.21% | -15.82% | -24.82% | -35.19% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $138,983K ÷ ($72,337K + $349,018K)
= 32.98%
ADMA Biologics Inc's return on total capital has shown a fluctuating trend over the years based on the provided data. The company experienced negative returns in the years ending December 31, 2020, 2021, and 2022, with percentages of -35.19%, -24.82%, and -15.82% respectively. However, the return on total capital improved significantly by the end of December 31, 2023, with a positive return of 1.21%. Notably, there was a substantial increase in the return on total capital by December 31, 2024, reaching 32.98%, indicating a notable growth in the company's profitability in that year.
Peer comparison
Dec 31, 2024